News Related to B-Cell Cancers

Related coverage linked through entity extraction aliases.

FDA Accepts Tirabrutinib Application for Relapsed Primary CNS Lymphoma

Feb 24, 2026

The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.

Indigenous CAR-T Therapy Marks Milestone for India's Cancer Care and Biotech Manufacturing

Feb 19, 2026

ImmunoACT's domestically manufactured CAR-T therapy has treated over 600 patients with relapsed or refractory B-cell malignancies since its 2023 approval, marking India's entry into advanced cellular therapy production.